
    
      A total number of 3206 patients will be randomized (1:1) to treatment arms. Patients will be
      recruited across seven countries in Europe (Spain, Italy, Germany, France, Hungary, Poland,
      and Czech Republic).

      Patients will be â‰¥65 years old and diagnosed with a type 1 myocardial infarction within 6
      months prior to study enrolment.

      Once the inclusion and exclusion criteria are confirmed, patients will be included in the
      study after signing informed consent.

      Randomization will take place within 6 months of the index event (AMI type I) in a 1:1 ratio
      to one of the two arms:

        -  Cardiovascular Polypill (containing Aspirin, Ramipril, and Atorvastatin)

        -  Usual care

      Patients will be followed up for a minimum of 2 years and a maximum of 4 years.

      There will be 3 follow up visits at month 6, 12 and 24 and telephone follow up calls at month
      18, 36 and 48
    
  